Alkermes announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1. ALKS 2680 is the company’s novel, investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency in orexin levels, and the presence of cataplexy, a sudden loss of muscle tone triggered by strong emotions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes price target lowered to $23 from $25 at UBS
- Biotech Alert: Searches spiking for these stocks today
- Alkermes narcolepsy drug ‘could be best-in-class,’ says Mizuho
- Alkermes price target raised to $50 at Jefferies after ‘excellent’ NT2 data
- Alkermes narcolepsy data better than expected, says Stifel
